Mobilsation kinetics following late afternoon dosing with plerixafor in patients with multiple myeloma or non-Hodgkin's lymphoma undergoing stem-cell mobilisation.

Trial Profile

Mobilsation kinetics following late afternoon dosing with plerixafor in patients with multiple myeloma or non-Hodgkin's lymphoma undergoing stem-cell mobilisation.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Plerixafor (Primary) ; Granulocyte colony-stimulating factors
  • Indications Multiple myeloma; Non-Hodgkin's lymphoma; Stem cell mobilisation
  • Focus Pharmacodynamics
  • Most Recent Events

    • 13 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top